Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate
Life Sciences ( IF 5.2 ) Pub Date : 2020-07-02 , DOI: 10.1016/j.lfs.2020.118033 Maryam Eskandarynasab 1 , Amir Hossein Doustimotlagh 2 , Nasrin Takzaree 3 , Shahroo Etemad-Moghadam 4 , Mojgan Alaeddini 4 , Ahmad Reza Dehpour 5 , Ramin Goudarzi 6 , Alireza Partoazar 5
Life Sciences ( IF 5.2 ) Pub Date : 2020-07-02 , DOI: 10.1016/j.lfs.2020.118033 Maryam Eskandarynasab 1 , Amir Hossein Doustimotlagh 2 , Nasrin Takzaree 3 , Shahroo Etemad-Moghadam 4 , Mojgan Alaeddini 4 , Ahmad Reza Dehpour 5 , Ramin Goudarzi 6 , Alireza Partoazar 5
Affiliation
|
The present study aimed to investigate the effects of phosphatidylserine liposomes (PSLs) and phosphatidylserine liposomes containing alendronate (AL-PSLs) on the improvement of methylprednisolone (MP) induced osteoporosis in a rat model. AL-PSLs formulation was prepared, characterized, and evaluated in different pH media to simulate gastrointestinal condition. Osteoporosis was induced by 3 weeks oral administration of MP (10 mg/kg) and then treatment by PSLs, AL-PSLs, and alendronate (AL). Bone metabolic and biomechanical markers were measured in treated rat groups. Also, Tartrate-resistant acid phosphatase (TRAP) staining and histomorphometry were evaluated on bone tissues of treated rats. AL-PSLs were obtained in a size range of 155 nm and negatively surface charge with an entrapment efficiency of 42%. The AL leakage from AL-PSLs did not exhibit a significant difference in acidic or basic media in comparison with the neutral condition. The concentrations of calcium, osteocalcin, bone alkaline phosphatase, and osteoprotegerin (OPG) of serum were significantly increased in PSLs and AL-PSLs treated groups compared to the MP group. Also, PSLs and AL-PSLs significantly improved the thickness and volume of the cortical and trabecular bone mass in treated groups. In addition, TRAP staining indicated a significant decrease of osteoclast number in osteoporotic rats treated with AL-PSLs and PSLs. In this study, AL-PSLs and even PSLs alone made a potential bone mechanical strength in glucocorticoid-induced bone loss more than AL in rats. In conclusion, our findings suggest that PSLs consumption with or without an anti-osteoporotic drug might be an applicable choice in control of osteoporosis.
中文翻译：
磷脂酰丝氨酸纳米脂质体抑制糖皮质激素诱导的骨质疏松症：与阿仑膦酸钠的潜在联合疗法
本研究旨在探讨磷脂酰丝氨酸脂质体（PSL）和含阿仑膦酸钠的磷脂酰丝氨酸脂质体（AL-PSL）对改善甲基强的松龙（MP）诱导的大鼠骨质疏松症的作用。在不同 pH 介质中制备、表征和评估 AL-PSL 制剂以模拟胃肠道条件。通过口服 MP (10 mg/kg) 3 周，然后用 PSL、AL-PSL 和阿仑膦酸钠 (AL) 治疗来诱导骨质疏松症。在治疗组的大鼠中测量骨代谢和生物力学标志物。此外，还对治疗大鼠的骨组织进行了抗酒石酸酸性磷酸酶（TRAP）染色和组织形态计量学评估。获得的 AL-PSL 尺寸范围为 155 nm，表面带负电荷，捕获效率为 42%。与中性条件相比，AL-PSL 的 AL 泄漏在酸性或碱性介质中没有表现出显着差异。与 MP 组相比，PSL 和 AL-PSL 治疗组的血清钙、骨钙素、骨碱性磷酸酶和骨保护素 (OPG) 浓度显着升高。此外，PSL 和 AL-PSL 显着改善了治疗组中皮质骨和小梁骨质量的厚度和体积。此外，TRAP 染色表明，用 AL-PSL 和 PSL 治疗的骨质疏松大鼠的破骨细胞数量显着减少。在这项研究中，AL-PSL 甚至单独的 PSL 在糖皮质激素引起的大鼠骨质流失中的潜在骨机械强度比 AL 更高。总之，我们的研究结果表明，服用或不服用抗骨质疏松药物的 PSL 可能是控制骨质疏松症的可行选择。
更新日期：2020-07-02
中文翻译：
磷脂酰丝氨酸纳米脂质体抑制糖皮质激素诱导的骨质疏松症：与阿仑膦酸钠的潜在联合疗法
本研究旨在探讨磷脂酰丝氨酸脂质体（PSL）和含阿仑膦酸钠的磷脂酰丝氨酸脂质体（AL-PSL）对改善甲基强的松龙（MP）诱导的大鼠骨质疏松症的作用。在不同 pH 介质中制备、表征和评估 AL-PSL 制剂以模拟胃肠道条件。通过口服 MP (10 mg/kg) 3 周，然后用 PSL、AL-PSL 和阿仑膦酸钠 (AL) 治疗来诱导骨质疏松症。在治疗组的大鼠中测量骨代谢和生物力学标志物。此外，还对治疗大鼠的骨组织进行了抗酒石酸酸性磷酸酶（TRAP）染色和组织形态计量学评估。获得的 AL-PSL 尺寸范围为 155 nm，表面带负电荷，捕获效率为 42%。与中性条件相比，AL-PSL 的 AL 泄漏在酸性或碱性介质中没有表现出显着差异。与 MP 组相比，PSL 和 AL-PSL 治疗组的血清钙、骨钙素、骨碱性磷酸酶和骨保护素 (OPG) 浓度显着升高。此外，PSL 和 AL-PSL 显着改善了治疗组中皮质骨和小梁骨质量的厚度和体积。此外，TRAP 染色表明，用 AL-PSL 和 PSL 治疗的骨质疏松大鼠的破骨细胞数量显着减少。在这项研究中，AL-PSL 甚至单独的 PSL 在糖皮质激素引起的大鼠骨质流失中的潜在骨机械强度比 AL 更高。总之，我们的研究结果表明，服用或不服用抗骨质疏松药物的 PSL 可能是控制骨质疏松症的可行选择。
京公网安备 11010802027423号